GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » Median PS Value

Daiichinkyo Co (STU:D4S) Median PS Value : €26.07 (As of Dec. 13, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Daiichinkyo Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €5.668. Daiichinkyo Co's 10-Year median PS Ratio is 4.5995. Therefore, the Median PS Value for today is €26.07.

As of today (2024-12-13), Daiichinkyo Co's share price is €27.99. Daiichinkyo Co's Median PS Value is €26.07. Therefore, Daiichinkyo Co's Price to Median PS Value for today is 1.07.

The historical rank and industry rank for Daiichinkyo Co's Median PS Value or its related term are showing as below:

STU:D4S' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.07   Med: 2.74   Max: 4.15
Current: 1.07

During the past 13 years, the highest Price to Median PS Value of Daiichinkyo Co was 4.15. The lowest was 1.07. And the median was 2.74.

STU:D4S's Price-to-Median-PS-Value is ranked worse than
64.05% of 523 companies
in the Drug Manufacturers industry
Industry Median: 0.9 vs STU:D4S: 1.07

Daiichinkyo Co Median PS Value Historical Data

The historical data trend for Daiichinkyo Co's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Median PS Value Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.80 6.66 7.30 12.21 19.77

Daiichinkyo Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.93 15.76 19.77 22.03 25.99

Competitive Comparison of Daiichinkyo Co's Median PS Value

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Price-to-Median-PS-Value falls into.



Daiichinkyo Co Median PS Value Calculation

Daiichinkyo Co's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=5.668*4.5995
=26.07

10-Year Median PS Ratio is 4.5995.
Daiichinkyo Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.668.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (STU:D4S) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Daiichinkyo Co's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=27.99/26.07
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co Median PS Value Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co Headlines

No Headlines